Prostat spesifik antijen değeri ≤ 20 ng/ml olan prostat adenokarsinomlu olgularda kemik metastazının değerlendirilmesinde gleason skorunun önemi

Abstract

Amaç: Bu çalışmada prostat spesifik antijen PSA değeri ≤ 20 ng/ml olan prostat kanserli olgularda kemik metastazın değerlendirilmesinde gleason skorunun önemini araştırdık.Gereç ve Yöntem: Kliniğimizde PSA yüksekliği ve anormal rektal muayene bulgusu nedeniyle transrektal ultrasografi eşliğinde 10 kadran prostat biyopsisi alınıp prostat adenokarsinomu tanısı alan, PSA değeri ≤ 20 olan olgular, gleason skoru ≤6 30 hasta ve >6 50 hasta olmak üzere iki gruba ayrıldı. Her iki grup yaş, total PSA değeri ve kemik sintigrafindeki metastaz açısından karşılaştırıldı.Bulgular: Gleason skoru ≤6 olan grupta yaş ortalaması 69.60 ± 6.56 iken gleason skoru >6 olan grupta yaş ortalaması 70.68 ± 8.34 idi p=0.153 . Gleason skoru ≤6 olan grupta ortalama PSA değeri 12.10 ± 4.57 mg/dl iken gleason skoru >6 olan grupta ortalama PSA değeri 13.11 ± 4.53 idi p=0.652 . Tüm olgularda sintigrafide kemik metastazı saptanma oranı % 31.25 iken bu oran gleason skoru ≤6 olan grupta % 6.6, gleason skoru > 6 olan grupta ise % 46.6 idi. p6 olan grupta metastaz saptanma oranının anlamlı olarak yüksek olduğu saptandı p 6 olan grupta kemik sintigrafisinde metastaz saptanma oranının anlamlı olarak yüksek olduğunu gözledik. PSA değeri 20 ng/ml’den küçük olsa bile gleason skoru > 6 olan olgularda metastaz taraması amaçlı kemik sintigrafi yapılmasını önermekteyiz

Keywords

• Prostat kanseri,Gleason skoru,Prostat spesifik antijen,Kemik sintigrafisi

The importance of gleason score in the evaluation of bone metastasis in prostate adenocarcinoma patients whose prostate specific antigen level ≤ 20 ng / ml

Abstract

Objective: In this study, we investigated the importance of gleason score in detecting bone metastasis in prostate adenocarcinoma patients whose prostate-specific antigen PSA level ≤ 20 ng / ml Materials and Methods: Prostate adenocarcinoma cases diagosed by 10-quadrant transrectal ultrasound-guided prostate biopsy were divided into 2 groups of total gleason score ≤6 30 patients and total gleason score >6 50 patients . Both groups compared in terms of age, total PSA and metastasis on bone scintigraphy.Results: The mean age was 69.60 ± 6.56 in patients with gleason score ≤6 and 70.68 ± 8.34 in patients with gleason score > 6 p=0.153 . The mean PSA level was 12.10 ± 4.57 mg/ dl in patients with gleason score ≤ 6 and 13.11 ± 4.53 in patients with gleason score >6 p=0.652 . There was no singnificant difference in terms of age and total PSA however metastasis on bone scintigraphy was significantly higher in the patient with gleason score>6 p6 and PSA level ≤ 20 ng/ml. We suggest bone scintigraphy in prostate cancer patients with gleason score > 6 for metastatic evaluation even if PSA level is less than or equal to 20 ng/ml

Keywords

• Prostate cancer,Gleason score,Prostate spesific antigen,Bone scintigraphy

References

1. Boyle P, Dresler C. Preventing the lung cancer epidemic. Ann Oncol. 2005 Oct; 16(10):1565-6.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar- Apr;58(2):71-96.
3. Dinçel Ç. Üroonkoloji, Prostat kanserinde biyopsi. 1.Baskı. İzmir, Meta Basım Matbaacılık, 2007, p 45.
4. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol1989;142(1):71-74; dis- cussion 74-75.
5. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
6. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL.ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pat- hol 2005;29:1228-42.
7. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: Significant worldwide economic implica- tions M.D.Joseph, E. Oesterling. Urology 1995 Volume 46, Issue 3, Supplement 1, September Pages 26-33.
8. Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard NP, Toussi H. A study on staging bone scans in newly diagnosed prostate cancer. Urol Int. 2006;76(3):209- 12.

9. Prostate cancer. A.Heidenreich (chairman), M. Bolla, S. Jo- niau M.D. Mason, V. Matveev, N. Mottet, H-P. Schmid T.H. van der Kwast, T. Wiegel, F. Zattoni European Association of Urology 2010 p 113.
10. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on pros- tate cancer. Eur Urol 2005;48:546–51.
11. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O.Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002 Oct;168(4 Pt 1):1423-6.
12. Hricak H, Tohenty R.F: Neoplasms of Prostate Gland. Pollack H, Clinical Urography. WB Saunders 1990. vol 2.pp.1381-1403.
13. Carter, H.B. and A.W. Partin, 2002. Diagnosis and Staging of Prostate Cancer. Walsh, P.C., A.B. Retik, E.D. Vaughan and A.J. Wein (Ed): Campbell’s Urology 8th. Ed WB Saun- ders,2002, vol 4, pp.3055-3079.
14. Jacobson AF. Bone scanning in metastatic dis- ease. In: Co- lier BD Jr, Fogelman I, Rosenthal L, skeletal nuclear medi- cine. Mosby, St. Louis, MI, USA,1996;chapter 6, p: 87-123
15. Strohmaier WL, Keller T, Bichler KH. Follow-up in pros- tate cancer patients: which parameters are necessary? Eur Urol 1999; 35: 21–5.
16. Freitas JE, Gilvydas R, Ferry JD, Gonzalez JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991;32:1387-1390.
17. Middleton RG, Thompson IM, Austenfeld MS, et al: Pros- tate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. J.Urol:1995;154:2144-8.
18. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: A multidisciplinary Perspec- tive. Radiology 2007:43;28-53.
19. Spencer JA, Chang WJ, Hudson E, Boon AP, Whelan P: Prostate specific antigen level and Gleason score in predic- ting the stage of newly diagnosed prostate cancer. Br J Ra- diol 1998; 71:1130–1135.
20. Kemp P.M., Maquire G.A., Bird N.J. Which patients with prostatic carcinoma require a staging bone scan? Br. J. Urol. 1997; 79:770-76.
21. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Pre- dicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate prostate cancer: pros- tate spesific antigen is superior to all other clinical parama- ters. J urol 1991; 145: 313-18.
22. Oesterling JE, Martin SK, Bergstralh. EJ, Lowe FC. The use of prostate- specific antigen in staging patientswith newly diagnosed prostate cancer. JAMA. 1993; 269: 57-60.
23. Axel Heidenreich , Gunnar Aus , Michel Bolla , Steven Jo- niau, Vsevolod B. Matveev , Hans Peter Schmid , Filliber- to Zattoni EAU Guidelines on Prostate Cancer 2010 p11.
24. Makarov DV, Sanderson H, Partin AW, Epstein JI. Glea- son score 7 prostate cancer on needle biopsy: is the prog- nostic difference in Gleason scores 4 + 3 and 3 + 4 inde- pendent of the number of involved cores? J Urol. 2002 Jun;167(6):2440-42.
25. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer sta- ging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8.
26. Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kine- buchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radio- nuclide bone scan for prostate cancer patients in Japan. Int J Urol. 2005 Aug;12(8):728-32.
27. Aus G, Abbou CC, Bolla M, Heidenreich A,van Poppel H, Schmid H-P, Wolff JM, Zattoni F. Guidelines on prostate cancer. European Association of Urology Guidelines, 2006.
28. Rusu D, Rusu V, Stefănescu C, Rusu M, Răileanu I, Stătescu AM. [A comparaison between the total PSA, the Gle- ason score and the bone scintiscan results for different age groups]. Rev Med Chir Soc Med Nat Iasi. 2010 Apr- Jun;114(2):476-83.
29. Ritenour CW, Abbott JT, Goodman M, Alazraki N, Mars- hall FF, Issa MM. The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. ScientificWorldJour- nal. 2009 Oct 2;9:1040-5.
30. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice state- ment: 2009 update. J Urol. 2009 Nov;182(5):2232-41.